2/5/2025, 11:09:03 am

Buy Ajanta Pharma; target of Rs 3180: Choice Equity Broking

Choice Equity Broking has revised Ajanta Pharma's FY26E/FY27E earnings estimates downward by 6.2%/6.1% due to higher promotional and employee expenses amid expansion. The brokerage maintains a BUY rating with a revised target price of INR 3,180, reflecting PE-based and DCF-based valuations, as EBITDA margin improvements are expected post-FY27E.